Key result
Catheter ablation cuts appropriate ICD shocks ~34% and VT recurrence versus AADs, without affecting mortality.
Why the study?
Catheter ablation has emerged as a potential first-line therapy for ventricular tachycardia, but whether it is superior to antiarrhythmic drug therapy regarding clinical outcomes remained to be systematically assessed.
Does catheter ablation reduce appropriate ICD shocks, recurrent VT, and all-cause mortality compared to antiarrhythmic drug therapy in patients with ventricular tachycardia?
Does catheter ablation reduce appropriate ICD shocks, recurrent VT, and all-cause mortality compared to antiarrhythmic drug therapy in patients with ventricular tachycardia?
Catheter ablation is superior to antiarrhythmic drug therapy for reducing VT recurrence and appropriate ICD shocks in patients with ventricular tachycardia, though it does not improve overall mortality.
Answers are grounded in this paper and cite their sources.
Supports preferring catheter ablation over antiarrhythmic drugs to reduce ICD shocks and VT recurrence; reinforces consensus from prior randomized trials.
Background Ventricular tachycardia (VT) is a life-threatening arrhythmia, particularly in patients with structural heart disease. Standard management includes implantable cardioverter-defibrillators (ICDs) and antiarrhythmic drugs, but catheter ablation (CA) has emerged as a potential first-line therapy due to its ability to modify the arrhythmogenic substrate and reduce VT recurrence. Purpose This systematic review and meta-analysis aimed to assess whether catheter ablation is superior to antiarrhythmic drug therapy in the management of VT, focusing on their impact on clinical outcomes and treatment strategies. Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials (RCTs) comparing catheter ablation with antiarrhythmic drug therapy for VT management. Statistical analysis was carried out utilizing Review Manager version 5.4 and R version 4.2.2. Heterogeneity was assessed with I² statistics; p-values inferior to 0.05 and I²>25% were considered significant heterogeneity. The primary outcomes assessed included appropriate ICD shocks, recurrent VT, and all-cause mortality. Results Ten RCTs met the inclusion criteria, encompassing 1,519 participants, of whom 748 underwent CA. The CA group showed a significant reduction in appropriate ICD shocks (RR 0.66; CI 0.50-0.88; p = 0.005; Figure 1A) and VT recurrence (RR 0.81; CI 0.70-0.92; p = 0.002; Figure 1B) compared to antiarrhythmic therapy. However, no significant difference was observed in all-cause mortality (RR 0.92; CI 0.73-1.14; p = 0.439; Figure 2). Conclusion This systematic review and meta-analysis suggest that catheter ablation is more effective than antiarrhythmic drug therapy in reducing VT recurrence and ICD interventions, but does not impact overall mortality.
No takes yet. Share an insight, caveat, or question.
Lucena et al. (2025) studied this question. Catheter ablation reduced appropriate ICD shocks by 34% and VT recurrence by 19% versus antiarrhythmic drugs, with no mortality difference.
Synapse has enriched 10 related papers. Consider them for comparative context: